Target intelligence / Profile preview

Galactosylceramide sulfotransferase (GAL3ST1)

Target
GAL3ST1
Molecular classification
Enzyme, Sulfotransferase family
01

Overview

Galactosylceramide sulfotransferase (GAL3ST1) is an enzyme responsible for the transfer of sulfate groups to position 3 of non-reducing beta-galactosyl residues in glycerolipids and sphingolipids, resulting primarily in the synthesis of galactosylceramide sulfate (sulfatide)[1][2][3][6][9]. Sulfatide is a major lipid component of the myelin sheath in the central and peripheral nervous systems and seminolipid in the male reproductive system[1][9]. GAL3ST1 acts chiefly on galactosylceramide and related glycolipids, and dysfunction can potentially contribute to myelin-related pathologies. Activity of this sulfotransferase is increased in renal cell carcinoma[3]; therefore, it may serve as a biomarker for certain cancers and neurological disorders. GAL3ST1 is encoded on chromosome 22q12.2, and its canonical protein product consists of 423 residues[1][4].

Other names
galactose-3-O-sulfotransferase 1CSTGalCer sulfotransferase3'-phosphoadenosine-5'-phosphosulfate:GalCer sulfotransferasecerebroside sulfotransferase3'-phosphoadenylylsulfate:galactosylceramide 3'-sulfotransferasegalactosylceramide sulfate synthaseG3ST1
02

Biological functions

Sulfation of membrane glycolipidsSynthesis of galactosylceramide sulfate (sulfatide), a key component of the myelin sheathSynthesis of seminolipid in spermatocytesModification of glycerolipids and sphingolipids by transfer of sulfate group
03

Disease associations

Neurodegenerative diseaseRenal cell carcinoma (notable increased activity)Other (demyelinating disorders by implication from its central role in myelin sheath composition)
04

Safety considerations

Loss of function may be linked to myelin sheath disordersOveractivity may be a biomarker in renal cell carcinoma
05

Biomarkers

Sulfatide levels (potential biomarker in neurological and renal disorders)

Beyond the preview

Go deeper on Galactosylceramide sulfotransferase (GAL3ST1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Galactosylceramide sulfotransferase (GAL3ST1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call